Kenvue Inc. (NYSE:KVUE) Position Increased by Mariner LLC

Mariner LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 50.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 259,420 shares of the company's stock after purchasing an additional 87,321 shares during the quarter. Mariner LLC's holdings in Kenvue were worth $5,538,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Kiley Juergens Wealth Management LLC raised its holdings in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock valued at $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its position in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock worth $303,000 after purchasing an additional 500 shares during the last quarter. White Pine Capital LLC raised its stake in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after purchasing an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators lifted its position in shares of Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after purchasing an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. Barclays reduced their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th. Citigroup raised their price objective on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research note on Monday, April 14th. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Finally, Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $24.42.

Kenvue Price Performance

NYSE KVUE traded down $0.20 on Thursday, reaching $22.74. 13,303,334 shares of the stock traded hands, compared to its average volume of 17,103,478. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market cap of $43.63 billion, a price-to-earnings ratio of 42.91, a P/E/G ratio of 2.62 and a beta of 1.02. The firm's fifty day simple moving average is $22.99 and its 200 day simple moving average is $22.42. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date is Wednesday, May 14th. Kenvue's payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.